At Bristol Myers Squibb, Chris leads the company's Global Market Access, Pricing, and Value Demonstration (MAx) function, which is focused on defining and articulating the value of the BMS portfolio to payers and other access stakeholders around the globe and developing innovative solutions to help ensure appropriate patient access. Immediately before moving into his current role, he led the MAx function at BMS in the United States. Chris has 30 years of experience in access, pricing, government affairs, and reimbursement at the global and market levels and has held leadership roles at the global and market levels at small to large biopharmaceutical companies, including Amgen, MERCK, and MorphoSys. In addition to his responsibilities at BMS, Chris is a Member of the Board of Directors at the National Pharmaceutical Council and the ACCESS Forum.